PROM1 and central nervous system cancer: In addition, it cannot be excluded that the role of CD133 as a marker of CSCs may differ according to tumor type: for instance, in gliomas and glioblastomas, CD133 expression has been shown not to be an absolute requirement for tumor initiation and progression [36,37], thus leading to hypothesize that it could just characterize populations with enhanced proliferative potential.